Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ningbo Univ. HDAC6 compound 6c
- Development stage
- Preclinical
- Lead developer
- Ningbo University
01
Overview
Ningbo Univ. HDAC6 compound 6c: sourced facts only. name: "The leading compound 6c could direct bind to HDAC6, and selectively inhibits HDAC6 with a high affinity in vitro." [PMID:42763962]; target: "The leading compound 6c could direct bind to HDAC6, and selectively inhibits HDAC6 with a high affinity in vitro." [PMID:42763962]; developer: "Translational Medicine Center of Pain, Emotion and Cognition, Health Science Center, Ningbo University, Ningbo, 315211, China." [PMID:42763962]; stage: "Furthermore, 6c effectively prevented HDAC6-driven α-tubulin and Hsp90 deacylation, as well as cognitive impairments in Aβ1-42 oligomer-treated mice." [PMID:42763962]
02
Targets
HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on Ningbo Univ. HDAC6 compound 6c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ningbo Univ. HDAC6 compound 6c.